VTRS · 10-Q · 2026Q3 · Full report

Acquisition / Partnership / Divestiture

Viatris Inc · 2026-11-05 · Importance 59 · Surprise 60 · Matches filing data

On October 8, 2026, Viatris agreed to acquire all outstanding Pacira shares for $36.50 per share in cash, representing an aggregate equity value of $1.65 billion. The company commenced its offer on October 30, which is scheduled to expire on November 16, 2026, unless extended or terminated earlier. Viatris expects to fund the acquisition primarily with excess cash and the remainder with short-term borrowings. Closing is expected by the end of November 2026, subject to customary conditions, including tender of a majority of Pacira shares and expiration of the regulatory waiting period.

Key facts

• On October 8, 2026, Viatris agreed to acquire all outstanding Pacira shares for $36.50 per share in cash, representing an aggregate equity value of $1.65 billion. source
• On October 30, 2026, Viatris commenced an offer to purchase all issued and outstanding Pacira shares for $36.50 per share in cash, net of applicable withholding taxes and without interest. source
• The Pacira transaction requires customary closing conditions, including tender of a majority of outstanding Pacira shares and expiration of the applicable regulatory waiting period, and is expected to close by the end of November 2026. source
• The Pacira offer and withdrawal rights are scheduled to expire at one minute after 11:59 p.m. Eastern Time on November 16, 2026, unless extended or terminated earlier. source
• After the Pacira offer, Viatris will acquire any remaining Pacira shares through a merger for the same consideration. source
• Viatris recorded $5.0 million of acquired IPR&D expense in the third quarter of 2026 for an upfront licensing deal, compared with none in the prior-year quarter. source
• Viatris' acquired IPR&D expense for the nine months ended September 30, 2026 was $5.2 million, versus $10.0 million in the prior-year period; the current-period expense related to an upfront payment for a licensing deal. source
• Viatris' prior-year acquired IPR&D expense included an upfront licensing payment for rights to cenerimod in Japan, South Korea and certain Asia-Pacific countries. source

Impact estimates